Gynecol Oncol. 2013 May 22. pii: S0090-8258(13)00736-1. doi: 10.1016/j.ygyno.2013.05.003. [Epub ahead of print]
Keeping it simple: Genetics referrals for all invasive serous ovarian cancers.
SourceDivision of Gynecologic Oncology, Princess Margaret Hospital, University Health Network, Toronto, Canada; Department of Molecular Genetics, University of Toronto, Toronto, Canada. Electronic address: Rochelle.Demsky@uhn.ca.
OBJECTIVE:In the province of Ontario, all women diagnosed with invasive serous ovarian cancer are eligible for genetic testing for mutations in the BRCA1 and BRCA2 genes. This study aimed to determine the proportion of these women who are seen for genetic counseling and to identify potential predictors and barriers to having genetic counseling.
METHODS:All women who were diagnosed with invasive serous ovarian cancer and had genetic counseling at Princess Margaret Hospital (PMH) between 2002 and 2009 were identified. Logistic regressions and trend analyses explored age at diagnosis, year at diagnosis, and the time between diagnosis and genetic counseling. Genetic counseling outcomes were also examined.
RESULTS:Of 623 women diagnosed with invasive serous ovarian cancer, 144 (23%) were seen for genetic counseling. As age at diagnosis increased, the likelihood of genetic counseling decreased (p=0.005). With a more recent date of diagnosis, the probability of having genetic counseling increased (p=0.032) while the time to genetic counseling decreased (p=0.001). Of women who pursued genetic testing, 31% were found to have a BRCA1 or BRCA2 mutation, 16% of whom had no family history of breast or ovarian cancer.
CONCLUSIONS:Despite the availability of genetic testing, only a small proportion of women with invasive serous ovarian cancer were seen for genetic counseling. Over time, an improvement in the proportion of women being seen for genetic counseling was noted; however barriers to seeing women with a later age at diagnosis or those with no family history of breast or ovarian cancer clearly exist.
Copyright © 2013 Elsevier Inc. All rights reserved.
- [PubMed - as supplied by publisher]
No hay comentarios:
Publicar un comentario